Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Anxiety Disorders Pipeline Review 2016: Anxiety Disorders Pipeline Therapeutics Constitutes Close to 94 Molecules - Research and Markets

Research and Markets
Posted on: 12 Oct 16

Research and Markets has announced the addition of the "Anxiety Disorders - Pipeline Review, H2 2016" report to their offering.

Anxiety Disorders pipeline therapeutics constitutes close to 94 molecules. Out of which approximately 76 molecules are developed by Companies and remaining by the Universities

Institutes. Our latest report Anxiety Disorders - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Anxiety Disorders Anxiety disorders are a group of mental illnesses that cause people to feel excessively frightened, distressed, or uneasy during situations in which most other people would not experience these same feelings. Symptoms include feelings of panic, fear, and uneasiness, problems sleeping, shortness of breath, heart palpitations, nausea, muscle tension and dizziness. Treatment includes antidepressant medications. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 8, 7, 2, 45, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 3 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Anxiety Disorders Overview
  3. Therapeutics Development
  4. Pipeline Products for Anxiety Disorders - Overview
  5. Pipeline Products for Anxiety Disorders - Comparative Analysis
  6. Anxiety Disorders - Therapeutics under Development by Companies
  7. Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes
  8. Anxiety Disorders Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Anxiety Disorders - Products under Development by Companies
  13. Anxiety Disorders - Products under Investigation by Universities/Institutes
  14. Anxiety Disorders - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Ache Laboratorios Farmaceuticos S/A
  • Adamed Sp. z o.o.
  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Avineuro Pharmaceuticals, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Biohaven Pharmaceutical Holding Company Limited
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • Edgemont Pharmaceuticals, LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Fabre-Kramer Pharmaceuticals, Inc.
  • Gabather AB
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Humanetics Corporation
  • IntelGenx Corp.
  • Intra-Cellular Therapies, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • NeuroNascent, Inc.
  • Newron Pharmaceuticals S.p.A.
  • Nippon Chemiphar Co., Ltd.
  • Omeros Corporation
  • Otsuka Holdings Co., Ltd.
  • Pherin Pharmaceuticals, Inc.
  • Pragma Therapeutics
  • Protagenic Therapeutics Inc.
  • Suda Ltd
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Synchroneuron Inc.
  • TRImaran Pharma, Inc.
  • Turing Pharmaceuticals AG

For more information about this report visit

View source version on

Business Wire

Last updated on: 12/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.